Ajanta Pharma Limited

• Ajanta Pharma's Nomination & Remuneration Committee allotted 23,400 equity shares from exercised ESOP options. • The company's paid-up capital increased to ₹24.99 crore, comprising 12.50 crore share

Ajanta Pharma's Q1 FY27 consolidated revenue grew 25% YoY to ₹1,626 cr, with PAT up 31% to ₹334 cr. Board declared a 1st interim dividend of ₹32 per share (face value ₹2), totaling a payout of ₹400 cr